Working… Menu

Photodynamic Therapy in Occult-Only Lesions (POOL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00135837
Recruitment Status : Completed
First Posted : August 26, 2005
Last Update Posted : June 21, 2006
QLT Inc.
Information provided by:

Brief Summary:
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye. Verteporfin may stabilize the disease, by closing the blood vessels. This study will assess the efficacy and safety of verteporfin in patients with occult only lesions.

Condition or disease Intervention/treatment Phase
Age-Related Macular Degeneration Drug: Verteporfin for injection Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 202 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Phase 4 Study of the Effect of Verteporfin for Injection Therapy in Subjects With Occult With No Classic Choroidal NeoVascularization Secondary to Age-Related Macular Degeneration
Study Start Date : June 2003

Primary Outcome Measures :
  1. visual acuity measurements, baseline, 12 months

Secondary Outcome Measures :
  1. visual acuity measurements, fundus photographs and fluorescein angiography at baseline, 12 months; ophthalmic examinations, adverse events, vital signs, concomitant medications, 12 months

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 50 years or older
  • Must see better or equal to 34 letters (visual acuity)
  • Choroidal neovascularization (CNV) lesion must be occult only

Exclusion Criteria:

  • Evidence of classic CNV in the lesion
  • Prior treatment of disease in study eye
  • Have a history of moderate to severe hepatic impairment

Other protocol-defined exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00135837

Layout table for location information
Basel, Switzerland
Sponsors and Collaborators
QLT Inc.
Layout table for investigator information
Study Chair: Novartis Customer Information Novartis

Layout table for additonal information Identifier: NCT00135837     History of Changes
Other Study ID Numbers: CBPD952B2401
First Posted: August 26, 2005    Key Record Dates
Last Update Posted: June 21, 2006
Last Verified: June 2006
Keywords provided by Novartis:
Age related Macula Degeneration,
choroidal neovascularisation (CNV),
occult CNV lesion,
verteporfin for injection,
photodynamic therapy (PDT)
Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Choroidal Neovascularization
Retinal Degeneration
Retinal Diseases
Eye Diseases
Choroid Diseases
Uveal Diseases
Neovascularization, Pathologic
Pathologic Processes
Photosensitizing Agents
Dermatologic Agents